Compare Ryanair Holdings plc (RYAAY) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ryanair Holdings plc vs 10X Genomics Inc — how do they compare? Ryanair Holdings plc trades at $54.25 (market cap $27.58B), while 10X Genomics Inc trades at $67.59 (market cap $8.55B). The key difference: Ryanair Holdings plc is far larger — about 3.2× 10X Genomics Inc's market cap, and Ryanair Holdings plc pays a 1.65% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| RYAAY | TXG | |
|---|---|---|
Market Cap | $27.58B | $8.55B |
Sector | Industrials | Health |
52-Week High | $73.82 | $67.29 |
52-Week Low | $53.24 | $11.34 |
Enterprise Value | $24.53B | $8.08B |
Dividend Yield | 1.65% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RYAAY trades at $54.37, down 1.79% on the day, with a bearish technical signal from moving averages. The company reported mixed Q2 2026 earnings, missing EPS estimates but showing strong revenue growth trends. Recent news highlights operational challenges including traffic outlook reductions and cost pressures from unhedged fuel. Cash flow remains positive from operations but net cash flow turned negative in 2025 and 2026 projections.
The outlook is cautious due to near-term headwinds from fuel costs and competitive pricing, but long-term fundamentals remain solid with attractive valuation multiples. Investment opportunity exists for value-oriented investors given low P/E of 13.09 and strong profitability metrics. Key risks include oil price volatility and winter capacity constraints affecting profitability.
TXG trades at $65.60, up 4.71% today, with strong technical momentum showing bullish moving averages and key support at $63. Fundamentally, the company demonstrates improving trends with Q2 2026 earnings beating estimates and revenue growth guidance raised, though profitability remains negative with a -12.18% net margin. Recent patent victory against Parse Biosciences strengthens competitive positioning.
The outlook remains cautiously optimistic with analyst consensus at 45% buy ratings and $50.78 price target. Key opportunities include Atera platform adoption and consumables growth, while risks center on valuation premiums and ongoing profitability challenges. The stock trades near resistance at $67 with institutional interest showing mixed signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ryanair Holdings plc
Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
